Karuna Therapeutics, Inc. KRTX
At closeMar 15, 2024, 4:00 PM EDT
52-week range unavailable
- Market cap
- 12.60B
- Revenue (ttm)
- 654.00K
- Shares out
- 38.20M
- Forward P/E
- -36.49
- Volume
- 1.28M
- Open
- 329.75
- Previous close
- 329.83
- Day's range
- 329.75 – 329.97
- Beta
- 1.15
- Analysts
- Hold
- Price target
- 324.17 (-1.7%)
- Earnings date
- May 2, 2024
Key statistics
- Enterprise value
- 11.34B
- PEG ratio
- 0.33
- Price / sales
- 19264.94
- Price / book
- 10.01
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -100.00%
- Free cash flow
- -223.64M
- Total cash
- 1.26B
- Total debt
- 16.69M
- Return on equity
- -36.44%
- Short % of float
- 6.03%
- 50-day average
- 317.71
- 200-day average
- 230.08
Analyst view
Consensus: hold
- Target (low)
- 260.00
- Target (mean)
- 324.17
- Target (high)
- 330.00
- Strong buy2
- Buy1
- Hold15
- Sell0
- Strong sell0
Next earnings
May 2, 2024
Expected May 2, 2024. Consensus EPS estimate -3.06.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 2, 2024 | Mar 1, 2024 | -3.00 | — | — | — |
| Feb 22, 2024 | Dec 1, 2023 | -2.64 | — | — | — |
| Nov 2, 2023 | Sep 1, 2023 | -2.74 | — | — | — |
| Aug 3, 2023 | Jun 1, 2023 | -2.76 | — | — | — |
| May 4, 2023 | Mar 1, 2023 | -2.86 | — | — | — |
| Feb 23, 2023 | Dec 1, 2022 | -2.23 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 27, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 7, 2023 | B of A Securities | main | Buy | Buy |
| Aug 21, 2023 | Cantor Fitzgerald | reit | Neutral | Neutral |
| Aug 21, 2023 | Wells Fargo | init | — | Overweight |
| Aug 3, 2023 | Morgan Stanley | reit | Overweight | Overweight |
| Aug 3, 2023 | RBC Capital | main | Outperform | Outperform |
About Karuna Therapeutics, Inc.
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- karunatx.com
News
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday 
Cognizant Technology Solutions To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday 
S&P 500, Nasdaq 100 Aim For 8th Week Of Gains As Fed's Inflation Gauge Cools: What's Driving Markets Friday? 
Earnings Scheduled For November 2, 2023 
Stocks That Hit 52-Week Lows On Tuesday - Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2023
- Earnings Scheduled For August 3, 2023
- Earnings Scheduled For May 4, 2023
- Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Your note
Sign in to keep a note on KRTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRANNAN STEPHEN K | Officer | Sale | Mar 7, 2024 | 42,604 |
| BROWN JASON PARKER | Chief Financial Officer | Stock Award(Grant) | Sep 28, 2023 | 21,445 |
| COUGHLIN CHRISTOPHER J | Director | Stock Award(Grant) | Jun 19, 2023 | 990 |
| HEALY JAMES I | Director | Stock Award(Grant) | Jun 19, 2023 | 1,414,640 |
| IGNELZI TROY A | Chief Financial Officer | Sale | Aug 21, 2023 | 30,487 |
| JONAS JEFFREY M | Director | Sale | Aug 31, 2023 | 990 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.91% | 5,616,588 | 1.22B | Jun 29, 2023 |
| Capital International Investors | 10.60% | 3,992,549 | 865.78M | Jun 29, 2023 |
| Vanguard Group Inc | 8.22% | 3,097,899 | 671.78M | Jun 29, 2023 |
| Price (T.Rowe) Associates Inc | 7.07% | 2,661,492 | 577.14M | Jun 29, 2023 |
| T. Rowe Price Investment Management, Inc. | 6.58% | 2,479,035 | 537.58M | Jun 29, 2023 |
| Blackrock Inc. | 4.95% | 1,864,636 | 404.35M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Growth Fund Of America Inc | 6.46% | 2,433,857 | 527.78M | Jun 29, 2023 |
| Fidelity Growth Company Fund | 3.38% | 1,271,966 | 238.82M | Aug 30, 2023 |
| Vanguard Total Stock Market Index Fund | 2.67% | 1,006,660 | 218.29M | Jun 29, 2023 |
| Vanguard Small-Cap Index Fund | 2.18% | 821,610 | 178.17M | Jun 29, 2023 |
| Vanguard Specialized-Health Care Fund | 2.03% | 765,799 | 152.98M | Jul 30, 2023 |
| Price (T.Rowe) Health Sciences Fund | 1.96% | 736,804 | 159.78M | Jun 29, 2023 |